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The prognosis in RA has improved considerably over the last decade with the use of more effective therapies, such as low-dose methotrexate, leflunomide, and tumor necrosis factor-α (TNF-α) antagonists (etanercept, infliximab, adalimumab) .
9-11 These agents, especially when begun early in patients with moderate to severe RA, have been shown to significantly reduce symptoms and signs of inflammation and slow or halt joint damage. It appears likely that earlier therapy of RA also will reduce the frequency or severity of its extraarticular complications, including cardiac involvement (Table 109 .1).
Rheumatoid Arthritis as a Cardiovascular Risk Factor
Recent epidemiologic studies have shown that RA itself, especially when RF positive, confers a considerable risk for premature cardiovascular disease (CVD) and early mortality.
12-20 Most traditional CVD risk factors, including lipid and homocysteine levels, are similar in RA patients and wellmatched population controls.
17 Biomarkers of inflammation, however, such as C-reactive protein (CRP), fibrinogen, soluble intercellular adhesion molecule (sICAM), soluble TNF receptors (sTNFR) I and II, and osteoprotegerin, are increased in RA patients, as they are in CVD patients. 17 Similarly, markers for thrombosis, including fibrinogen, von Willebrand factor (vWF), tissue-type plasminogen activator (t-PA) antigen, and D-dimer, also have been found to be increased in RA patients. 21 Furthermore, immune dysregulation as evidenced by an expanded population of CD4 + CD28 − T lymphocytes has been found in the peripheral blood of RA patients and of patients with unstable angina, as well as in atherosclerotic plaques. 22 Endothelial dysfunction resulting from systemic immunologic and inflammatory factors have been demonstrated even in young patients with active RA, especially those positive for RF. 13, [23] [24] [25] [26] [27] Recent evidence suggests that successful treatment of RA with agents such as methotrexate or TNF antagonists improves inflammatory markers and endothelial cell function, and appears to reduce mortality from CVD. [28] [29] [30] [31] Similarly, lipid-lowering agents (statins) appear to reduce inflammatory indicators in RA patients. 32, 33 Therefore, a multidisciplinary approach to early assessment and vigorous treatment of both RA itself and other CVD risk factors is recommended. Recently, several studies have shown an increased risk of congestive heart failure (CHF) in RA patients, especially those with RF, which was not explained by traditional CVD risk factors or clinical ischemic heart disease.
35,36
Rheumatoid Arthritis Therapies and the Heart Drugs used to treat RA (and other arthritides and connective tissue diseases) may have deleterious effects on the cardiovascular system. It is well established that long-term corticosteroid use promotes atherosclerosis.
37,38 Nonsteroidal antiinflammatory drugs (NSAIDs) may induce or worsen hypertension by virtue of their effects on renal function. Recently, selective cyclooxygenase (COX)-2 inhibitors have been found to significantly increase the risk of myocardial infarction (MI) and stroke, and it is still unclear whether some older NSAIDs also may confer similar risks.
39 Longterm use of chloroquine and, less often, hydroxychloroquine, in RA and systemic lupus erythematosus (SLE) rarely may cause a cardiomyopathy. 40 Paradoxically, methotrexate, whose therapeutic effect appears to be inhibition of adenosine receptors, rarely may induce an accelerated rheumatoid nodulosis syndrome, including many of the cardiac complications described below. 41, 42 Concomitant use of hydroxychloroquine may prevent this complication of methotrexate. 42 Finally, the newly introduced TNF antagonists have been found to worsen congestive heart failure and should not be used in such patients.
43,44
Cardiac Complications of Rheumatoid Disease PERICARDIAL DISEASE Pericardial disease is common in RA, with inflammation, granuloma formation, fibrous thickening, or small effusions detected in approximately 30% of patients during life by echocardiography and in similar frequency at necropsy. However, clinically evident pericarditis with chest pain, fever, and an auscultatory rub is infrequent, occurring in only 2% to 4% of patients.
45-48
CONSTRICTIVE PERICARDITIS Constrictive pericarditis due to pericardial thickening and contracture or enlarging effusion is also infrequent but life threatening. 47, 49, 50 The earliest symptoms are usually those of right-sided heart failure with progressive pedal edema and ascites. Later, or when pericardial fluid accumulates rapidly (tamponade), symptoms of left-sided cardiac failure predominate and include dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Findings on examination include a rapid, weak pulse with paradox, distended jugular veins accentuated during inspiration (Kussmaul's sign), distant heart sounds, hepatomegaly, and, less frequently, a pericardial rub or knock. Clinical suspicion is most important in diagnosis and should lead to a prompt echocardiographic study, which, if not definitive, should be followed by cardiac catheterization with pressure studies. In urgent situations where tamponade is suspected, emergency pericardiocentesis or pericardial window may provide a diagnosis and be lifesaving. Rheumatoid pericardial effusions are typically bloody, with elevated white blood cell counts (2000-10,000/mm 3 ), low or absent glucose levels, and low complement levels.
51
Bacterial, mycobacterial, and fungal infections always should be excluded by appropriate stains and cultures of the pericardial fl uid, as RA patients are often taking corticosteroids or other immunosuppressive drugs.
52
Relief of cardiac compression and prevention of recurrence are the primary therapeutic goals. Surgical stripping of the pericardium is usually necessary for constrictive pericarditis or refractory compressive pericardial effusions. 47, 50 Before surgery, or when surgery is contraindicated, high doses of oral or IV corticosteroids (60-100 mg prednisone equivalent/day), and at times cyclophosphamide (2 mg/kg/ day orally or 750-1000 mg IV monthly), should be given to prevent reaccumulation of fluid. 47 These drugs are not effective for constrictive pericarditis without effusion. 
